Subtype
Ovarian Carcinoma
CI-CAN-00003517Explore in graph →
270 active trials2 approved drugs24 evidence items
- NCIt
- C4908
- DOID
- 2152
- DOID
- 4001
- MeSH
- D000077216
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003517Explore in graph →
Clinical trials
895 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00853307 | MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma | completed | Phase 2 | 31 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 8, 2022 | clinicaltrials |
| NCT02889900 | Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer(CONCERTO) | completed | Phase 2 | 62 | AstraZenecaINDUSTRY | 1 | Mar 8, 2022 |
| clinicaltrials |
| NCT00096200 | Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2022 | clinicaltrials |
| NCT00886691 | Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 150 | GOG FoundationNETWORK | 1 | Feb 4, 2022 | clinicaltrials |
| NCT02657928 | Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer | completed | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT00888615 | Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 58 | GOG FoundationNETWORK | 1 | Oct 20, 2021 | clinicaltrials |
| NCT01720173 | Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 30 | Gynecologic Oncology GroupNETWORK | 1 | Oct 20, 2021 | clinicaltrials |
| NCT01853644 | Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer(TIVO) | completed | Phase 2 | 31 | Northwestern UniversityOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT02853318 | Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 40 | Roswell Park Cancer InstituteOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT03685695 | Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT01146795 | Neoadjuvant Therapy for Ovarian Cancer | completed | Phase 2 | 32 | Jason D. WrightOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT02022917 | Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer | completed | Phase 2 | 22 | Chang Gung Memorial HospitalOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT01519869 | Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma | completed | Phase 2 | 28 | Rachel MillerOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT00551070 | Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Dec 3, 2020 | clinicaltrials |
| NCT02283658 | Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Oct 23, 2020 | clinicaltrials |
| NCT01199263 | Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2020 | clinicaltrials |
| NCT01611558 | Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer | completed | Phase 2 | 40 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 13, 2020 | clinicaltrials |
| NCT01711970 | A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer | completed | Phase 1 / Phase 2 | 38 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 1 | Apr 24, 2020 | clinicaltrials |
| NCT00305695 | Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries | completed | Phase 2 | 160 | Gynecologic Oncology GroupNETWORK | 1 | Mar 24, 2020 | clinicaltrials |
| NCT01716715 | Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2020 | clinicaltrials |
| NCT02315430 | Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2020 | clinicaltrials |
| NCT00979992 | Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 2 | Feb 19, 2020 | clinicaltrials |
| NCT01091636 | Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer | completed | Phase 2 / Phase 3 | 184 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 17, 2020 | clinicaltrials |
| NCT00214058 | Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer | completed | Phase 2 | 36 | University of Wisconsin, MadisonOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT00445887 | Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer | completed | Phase 2 | 60 | Gynecologic Oncology GroupNETWORK | 1 | Nov 19, 2019 | clinicaltrials |
| NCT01666444 | VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | Phase 2 | 297 | CelgeneINDUSTRY | 1 | Sep 26, 2019 | clinicaltrials |
| NCT01663857 | A Study LY2228820 for Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 118 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 11, 2019 | clinicaltrials |
| NCT01196429 | Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 3 | Aug 8, 2019 | clinicaltrials |
| NCT00023712 | Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01305213 | Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | completed | Phase 2 | 107 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2019 | clinicaltrials |
| NCT00022659 | Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00025155 | Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy | completed | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00053365 | Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00113373 | Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer | completed | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00429793 | Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00093626 | Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00132067 | Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00993616 | Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01468909 | Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | completed | Phase 2 | 106 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01540565 | Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00436501 | VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 1 / Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Feb 26, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT00939809 | A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Jan 15, 2019 | clinicaltrials |
| NCT00278343 | Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 2 | Aug 29, 2018 | clinicaltrials |
| NCT00467051 | Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors | completed | Phase 2 | 20 | Children's Oncology GroupNETWORK | 4 | Aug 29, 2018 | clinicaltrials |
| NCT00301756 | Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2018 | clinicaltrials |
| NCT02107950 | Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma | completed | Phase 2 | 71 | SOTIO a.s.INDUSTRY | 3 | Aug 15, 2018 | clinicaltrials |
| NCT01091428 | Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer | completed | Phase 2 | 191 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 4, 2018 | clinicaltrials |
| NCT01764802 | Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer | completed | Phase 2 | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 30, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Apr 8, 2022source: clinicaltrials